Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Raw Materials: 2023-2024

Historic Raw Materials for Zevra Therapeutics (ZVRA) over the last 1 years, with Sep 2024 value amounting to $4.5 million.

  • Zevra Therapeutics' Raw Materials was N/A to $4.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $4.5 million, marking a year-over-year change of. This contributed to the annual value of $2.9 million for FY2023, which is N/A change from last year.
  • According to the latest figures from Q3 2024, Zevra Therapeutics' Raw Materials is $4.5 million, which was down 5.66% from $4.8 million recorded in Q2 2024.
  • Zevra Therapeutics' 5-year Raw Materials high stood at $4.8 million for Q2 2024, and its period low was $2.9 million during Q4 2023.
  • For the 2-year period, Zevra Therapeutics' Raw Materials averaged around $4.1 million, with its median value being $4.3 million (2024).